Jet Biotech disclosed its semi-annual report on August 30. The company achieved operating income of 277 million yuan in the first half of the year, an increase of 3.47%; net profit attributable to shareholders of listed companies was 208.16,600 yuan, a year-on-year decrease of 55.08%; and basic earnings per share were 0.15 yuan/share. During the reporting period, the company's performance was mainly affected by the increase in fixed costs such as depreciation and electricity costs due to the full commissioning of the automated production line in 2026, as well as the increase in sales, management and R&D expenses due to the development of new markets, the layout of cell and gene therapy, and filtration and purification fields. Furthermore, the continued decline in the US dollar exchange rate has led to an increase in exchange losses, further increasing the pressure on financial expenses.

Jet Biotech disclosed its semi-annual report on August 30. The company achieved operating income of 277 million yuan in the first half of the year, an increase of 3.47%; net profit attributable to shareholders of listed companies was 208.16,600 yuan, a year-on-year decrease of 55.08%; and basic earnings per share were 0.15 yuan/share. During the reporting period, the company's performance was mainly affected by the increase in fixed costs such as depreciation and electricity costs due to the full commissioning of the automated production line in 2026, as well as the increase in sales, management and R&D expenses due to the development of new markets, the layout of cell and gene therapy, and filtration and purification fields. Furthermore, the continued decline in the US dollar exchange rate has led to an increase in exchange losses, further increasing the pressure on financial expenses.